Resverlogix Corp RVXCF

Primary Symbol: T.RVX

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp > Sarah gone, dr wong gone

<< Previous

Bullboard Posts

Next >>

Comment by narmacon Aug 28, 2022 7:30pm

216 Views

Post# 34925726

RE:Sarah gone, dr wong gone

,,Hepalink cleaning out some insiders setting up for their major move I assume. The Chinese will outsmart our CEO!,,Watch and see!,,Its not the first day in the Market for these guys or ourselves.

<< Previous

Bullboard Posts

Next >>

One of the strongest contenders to lead Canada’s cannabis market